Regenerative Medicine's Next Frontier: Innovation & Investment

In this episode of Bench to Breakthrough, Accelagen CEO Greg Plunkett welcomes Silvio Tiziani, CEO of the Centre for Commercialisation of Regenerative Medicine (CCRM Australia), for an in-depth discussion on the future of regenerative medicine and advanced therapies in Australia. The conversation explores how cell and gene therapies are transforming patient outcomes, while highlighting the critical role that commercialization planning, manufacturing infrastructure, and ecosystem coordination play in bringing scientific discoveries to market. Silvio shares insights from the successful Canadian CCRM model and explains how Australia can strengthen its regenerative medicine sector through greater collaboration, workforce development, and strategic investment. The episode also examines Australia's evolving position in the global life sciences landscape and the opportunities available to attract talent, capital, and innovation. Before the main discussion, Greg reviews proposed changes to Australia's R&D Tax Incentive program and their potential impact on emerging biotech companies and investors.“The Bench 2 Breakthrough Podcast” is the official podcast of Accelagen, created to share real-world insights from the clinical and regulatory front lines of biotech and pharmaceutical development. Hosted by Accelagen founder and CEO Greg Plunkett alongside co-host Rosa Plunkett, the podcast explores global, regional, and local industry news, emerging challenges, and new opportunities shaping the CRO landscape. Each episode blends practical experience with thoughtful discussion, featuring expert guests and perspectives that help sponsors navigate development pathways more efficiently. From early discovery to clinical execution, Bench 2 Breakthrough is about turning scientific progress into meaningful outcomes for patients.Accelagen is a Melbourne-based, award-winning Contract Research Organisation (CRO) specializing in end-to-end clinical trials, regulatory affairs, and biometrics for pharmaceutical and biotechnology companies. Founded in 2010, it supports Phase I-IV trials and offers strategic guidance for drug and medical device development. We believe the future of human health needs a fresh, future-focused approach. We challenge existing conventions to deliver commercially savvy and patient-centric outcomes for leading biopharmaceutical and medical device companies in the fast-growing global trials market across Australia, North America, Asia Pacific, and Europe.